As PARP1 inhibition can increase Fra-1 expression without affecting c-Jun expression (92), AP-1 (Fra-1/c-Jun) inhibition combined with PARP1 inhibition therapy may serve as a new joint therapy for breast and ovarian cancer patients. Here, FOSL1 is linked to ovarian carcinoma.